Your browser is no longer supported. Please, upgrade your browser.
AbCellera Biologics Inc.
Index- P/E- EPS (ttm)- Insider Own23.30% Shs Outstand269.70M Perf Week-0.27%
Market Cap6.91B Forward P/E- EPS next Y-0.00 Insider Trans-20.27% Shs Float182.88M Perf Month-15.69%
Income- PEG- EPS next Q0.11 Inst Own37.20% Short Float4.15% Perf Quarter-29.12%
Sales431.24M P/S16.02 EPS this Y415.00% Inst Trans3.39% Short Ratio6.28 Perf Half Y-
Book/sh3.55 P/B7.30 EPS next Y-100.00% ROA- Target Price- Perf Year-
Cash/sh2.57 P/C10.07 EPS next 5Y- ROE- 52W Range23.20 - 71.91 Perf YTD-35.64%
Dividend- P/FCF- EPS past 5Y- ROI13.60% 52W High-63.98% Beta-
Dividend %- Quick Ratio10.30 Sales past 5Y- Gross Margin- 52W Low11.64% ATR2.01
Employees206 Current Ratio10.30 Sales Q/Q4253.50% Oper. Margin- RSI (14)42.80 Volatility6.67% 7.22%
OptionableYes Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume3.55 Prev Close24.84
ShortableYes LT Debt/Eq0.00 EarningsMay 13 AMC Payout- Avg Volume1.21M Price25.90
Recom1.60 SMA20-10.94% SMA50-11.07% SMA200-28.51% Volume4,286,777 Change4.27%
Jan-05-21Initiated SVB Leerink Outperform $45
Jan-05-21Initiated Stifel Buy $59
Jan-05-21Initiated Credit Suisse Outperform $52
Jan-05-21Initiated BMO Capital Markets Outperform $48
Jan-05-21Initiated Berenberg Buy $53
Jun-10-21 05:11PM  
May-16-21 03:02AM  
May-14-21 08:48PM  
May-13-21 11:30PM  
May-11-21 04:05PM  
May-06-21 09:00AM  
May-04-21 09:31AM  
Apr-29-21 04:10PM  
Apr-21-21 04:05PM  
Apr-20-21 11:37AM  
Apr-15-21 07:49AM  
Apr-14-21 04:05PM  
Apr-12-21 04:05PM  
Apr-05-21 02:00PM  
Apr-01-21 09:00AM  
Mar-29-21 04:05PM  
Mar-25-21 11:51AM  
Mar-16-21 12:51PM  
Mar-13-21 01:00AM  
Mar-10-21 11:21AM  
Mar-05-21 03:30PM  
Feb-27-21 09:23AM  
Feb-17-21 04:05PM  
Feb-11-21 04:05PM  
Feb-10-21 04:15PM  
Feb-09-21 08:26PM  
Feb-03-21 04:05PM  
Jan-28-21 01:08PM  
Jan-27-21 07:22AM  
Jan-26-21 07:09AM  
Jan-21-21 08:27AM  
Jan-19-21 04:41PM  
Dec-21-20 09:00AM  
Dec-15-20 09:03PM  
Dec-11-20 05:39PM  
Dec-10-20 10:47PM  
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, AI-powered drug discovery platform searches and analyzes the database of natural immune systems to find antibodies that can be developed as drugs. As of December 31, 2020, the company had 103 discovery programs that are either completed, in progress, or under contract. It has a discovery partnership agreement with Eli Lilly and Company. AbCellera Biologics Inc. was founded in 2012 and is headquartered in Vancouver, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Thermopylae Holdings Ltd.10% OwnerJun 09Sale24.035,598,420134,530,03355,604,330Jun 10 05:14 PM
Hansen Carl L. G.Chief Executive OfficerJun 09Sale24.136,000,000144,770,323233,500Jun 10 05:11 PM
Lecault VeroniqueChief Operating OfficerJun 09Sale25.501,000,00025,500,000273,630Jun 10 05:01 PM
Booth AndrewChief Financial OfficerJun 09Sale25.501,200,00030,600,0000Jun 10 05:00 PM
Falconer EsterChief Technology OfficerJun 09Sale25.501,000,00025,500,0000Jun 10 05:00 PM
Stimart TrynChief Legal OfficerJun 09Sale25.501,000,00025,500,000250Jun 10 05:01 PM
Booth AndrewChief Financial OfficerJun 07Option Exercise0.261,200,000306,0001,200,000Jun 09 08:30 PM
Stimart TrynChief Legal OfficerJun 07Option Exercise0.811,000,000815,0001,000,250Jun 09 08:30 PM
Falconer EsterChief Technology OfficerMar 19Option Exercise0.031,000,00034,3001,000,000Apr 23 08:00 PM